Opinion|Videos|December 2, 2024

Genital Mycotic Infection Treatment and Adverse Effects

Key Takeaways

  • Genital mycotic infections on SGLT-2 inhibitors are typically managed with topical antifungals, continuing the inhibitor unless infections are severe or recurrent.
  • Addressing adverse effects of GLP-1 receptor agonists involves discussing therapy benefits, considering dose adjustments, or exploring alternative treatments to maintain efficacy.
SHOW MORE

Panelists discuss the treatment of a patient with type 2 diabetes who develops a genital mycotic infection while on an SGLT-2 inhibitor, weighing the options of treating with topical antifungals versus discontinuing the medication, as well as addressing concerns for a patient on a GLP-1 receptor agonist and RAAS inhibitor who is experiencing adverse effects such as bloating and nausea while considering the benefits of continuing therapy.

  1. In a patient with type 2 diabetes who develops a genital mycotic infection while on an SGLT-2 inhibitor, do you treat the infection with topical antifungals and continue the SGLT-2 inhibitor, or should the SGLT-2 inhibitor be discontinued?
  2. A patient on a GLP-1 receptor agonist and RAAS inhibitor is experiencing bloating, nausea, and weight loss and expresses a desire to stop treatment. How should you address their concerns and manage these adverse effects while considering the benefits of continued therapy?

Newsletter

Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.

Subscribe

Latest CME